This came after an investigation into the deaths of children from kidney issues in the West African country.

The health body is "conducting further investigation" with the firm, Maiden Pharmaceuticals, and Indian authorities.

It has also advised regulators to stop the sale of these syrups.

India's health ministry and drugs regulator are yet to comment on the WHO's product alert, which it published on its website.

The Indian Express newspaper reported that the Indian drug regulator had launched an investigation after it was informed of the issue on 29 September 2022.

ALSO READ: End of #Covid19 pandemic in sight: WHO

The WHO findings, announced by Director-General Tedros Adhanom Ghebreyesus on Wednesday, came after samples of each of the four cough syrups were tested. It identified the medicines as Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup.

The health body said that laboratory analysis had confirmed that the syrups contained "unacceptable amounts" of diethylene glycol and ethylene glycol, which are toxic to humans and can prove fatal when consumed.

The WHO said that so far, the products have been identified in the Gambia, but that they may have been distributed to other countries through informal markets.

"All batches of these products should be considered unsafe until they can be analysed by the relevant national regulatory authorities," it added.

India produces a third of the world's medicines, mostly in the form of generic drugs.

ALSO READ: Ban on indoor public smoking among changes as tobacco plan nears law

Home to some of the fastest growing pharmaceutical companies, the country is known as the "world's pharmacy" and meets much of the medical needs of African nations.

Reuters reported that Maiden Pharmaceuticals, which is based in the northern state of Haryana, exports its products to countries in Asia, Africa and Latin America.

Medical officers in the Gambia first raised the alarm in July after dozens of children were diagnosed with serious kidney problems.

The Gambia's director of health services, Mustapha Bittaye, told Reuters that the number of deaths had gone down in recent weeks and that the country had banned the sale of the products.

"However, until recently, some of the syrups were still being sold in private clinics and in hospitals," he was quoted as saying.

BBC